Biotech

All Articles

Amgen files initial period 3 gain for $400M chronic eczema drug

.Amgen has actually discussed (PDF) the first stage 3 information on its $400 million dermatitis dru...

Biogen, UCB file period 3 lupus gain after failing earlier trial

.Biogen and also UCB's bank on developing right into period 3 on the back of an unsuccessful researc...

Aptadir wishes new RNA inhibitors may reverse tricky cancers

.Italian biotech Aptadir Therapeutics has launched along with the assurance that its pipeline of pre...

Wave surfs DMD success to regulatory authorities' doors, sending stockpile

.Surge Life Sciences has met its own objective in a Duchenne muscle dystrophy (DMD) study, installin...

Sanofi picks new CSO from in-stealth biotech

.After a couple of years in biotech, Mike Quigley, Ph.D., is actually returning to the pharma crease...

Achilles drops cell treatment plan, supports for discharges after missing 'commercial practicality' objectives

.Achilles Therapies has torn up its technique. The English biotech is actually knocking off on its o...

Aligos heralds period 2 MASH succeed, slashing liver excess fat approximately 46%

.Aligos Therapies is actually advertising a midstage succeed in metabolic-dysfunction linked steatoh...

Basilea credit ratings $268M BARDA backing for antifungals, anti-biotics

.Basilea Pharmaceutica's job cultivating brand-new antifungals has obtained a notable improvement fr...

Capricor sells Europe civil liberties to late-stage DMD treatment for $35M

.Having presently scooped up the U.S. legal rights to Capricor Therapies' late-stage Duchenne muscle...

FDA scraps adcomm for Applied's uncommon illness drug

.After pushing back the decision meeting for Applied Rehabs' metabolic problem medication govorestat...